AR124442A1 - Regímenes de dosificación de inhibidores orales de alk2 - Google Patents
Regímenes de dosificación de inhibidores orales de alk2Info
- Publication number
- AR124442A1 AR124442A1 ARP210103589A ARP210103589A AR124442A1 AR 124442 A1 AR124442 A1 AR 124442A1 AR P210103589 A ARP210103589 A AR P210103589A AR P210103589 A ARP210103589 A AR P210103589A AR 124442 A1 AR124442 A1 AR 124442A1
- Authority
- AR
- Argentina
- Prior art keywords
- alk2
- oral
- dosing regimens
- inhibitors
- alk2 inhibitors
- Prior art date
Links
- 102100034111 Activin receptor type-1 Human genes 0.000 title abstract 4
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formas de dosificación de compuestos y sales farmacéuticamente aceptables de los mismos, que son inhibidores de la quinasa ALK2, que incluye formas mutantes de ALK2. También se describen métodos para usar las formas de dosificación orales en el tratamiento o prevención de una enfermedad o condición cuyo tratamiento podría beneficiarse con la inhibición de la quinasa ALK2 (por ejemplo, fibrodisplasia osificante progresiva y cáncer).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128635P | 2020-12-21 | 2020-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124442A1 true AR124442A1 (es) | 2023-03-29 |
Family
ID=82159826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103589A AR124442A1 (es) | 2020-12-21 | 2021-12-20 | Regímenes de dosificación de inhibidores orales de alk2 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4262791A1 (es) |
| JP (1) | JP2023554398A (es) |
| CN (1) | CN116600812A (es) |
| AR (1) | AR124442A1 (es) |
| AU (1) | AU2021409381A1 (es) |
| CA (1) | CA3205111A1 (es) |
| IL (1) | IL303812A (es) |
| MX (1) | MX2023007378A (es) |
| TW (1) | TW202241437A (es) |
| UY (1) | UY39578A (es) |
| WO (1) | WO2022140250A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017250302B2 (en) * | 2016-04-15 | 2021-01-21 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| ES2931537T3 (es) * | 2017-10-18 | 2022-12-30 | Blueprint Medicines Corp | Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina |
-
2021
- 2021-12-20 AR ARP210103589A patent/AR124442A1/es unknown
- 2021-12-20 WO PCT/US2021/064333 patent/WO2022140250A1/en active Application Filing
- 2021-12-20 JP JP2023536423A patent/JP2023554398A/ja active Pending
- 2021-12-20 TW TW110147756A patent/TW202241437A/zh unknown
- 2021-12-20 MX MX2023007378A patent/MX2023007378A/es unknown
- 2021-12-20 IL IL303812A patent/IL303812A/en unknown
- 2021-12-20 EP EP21911969.0A patent/EP4262791A1/en active Pending
- 2021-12-20 AU AU2021409381A patent/AU2021409381A1/en active Pending
- 2021-12-20 CN CN202180085872.0A patent/CN116600812A/zh active Pending
- 2021-12-20 CA CA3205111A patent/CA3205111A1/en active Pending
- 2021-12-20 UY UY0001039578A patent/UY39578A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007378A (es) | 2023-07-04 |
| JP2023554398A (ja) | 2023-12-27 |
| CA3205111A1 (en) | 2022-06-30 |
| CN116600812A (zh) | 2023-08-15 |
| WO2022140250A1 (en) | 2022-06-30 |
| EP4262791A1 (en) | 2023-10-25 |
| UY39578A (es) | 2022-07-29 |
| AU2021409381A1 (en) | 2023-08-03 |
| IL303812A (en) | 2023-08-01 |
| TW202241437A (zh) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121433T1 (el) | Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4 | |
| ECSP22046699A (es) | Inhibidores de kras g12c | |
| CY1119466T1 (el) | Παραγωγα ιμιδαζοθειαδιαζολης και ιμιδαζοπυραζινης ως αναστολεις του ενεργοποιουμενου απο πρωτεαση υποδοχεα 4 (par 4) για αγωγη συσσωματωσης αιμοπεταλιων | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| ECSP22014980A (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| CY1116927T1 (el) | Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| CL2019001337A1 (es) | Formulaciones farmacéuticas. | |
| CO2018008305A2 (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2021002640A (es) | Formas morficas de los inhibidores del factor d del complemento. | |
| UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| AR124442A1 (es) | Regímenes de dosificación de inhibidores orales de alk2 | |
| CY1121909T1 (el) | Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου | |
| ECSP18023544A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona |